These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
577 related articles for article (PubMed ID: 17299088)
1. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Gardenghi S; Marongiu MF; Ramos P; Guy E; Breda L; Chadburn A; Liu Y; Amariglio N; Rechavi G; Rachmilewitz EA; Breuer W; Cabantchik ZI; Wrighting DM; Andrews NC; de Sousa M; Giardina PJ; Grady RW; Rivella S Blood; 2007 Jun; 109(11):5027-35. PubMed ID: 17299088 [TBL] [Abstract][Full Text] [Related]
2. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models. Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567 [TBL] [Abstract][Full Text] [Related]
3. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. Schmidt PJ; Toudjarska I; Sendamarai AK; Racie T; Milstein S; Bettencourt BR; Hettinger J; Bumcrot D; Fleming MD Blood; 2013 Feb; 121(7):1200-8. PubMed ID: 23223430 [TBL] [Abstract][Full Text] [Related]
4. Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia. Olivera J; Zhang V; Nemeth E; Ganz T Blood Adv; 2023 Jul; 7(14):3339-3349. PubMed ID: 36995275 [TBL] [Abstract][Full Text] [Related]
5. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia. Nai A; Pagani A; Mandelli G; Lidonnici MR; Silvestri L; Ferrari G; Camaschella C Blood; 2012 May; 119(21):5021-9. PubMed ID: 22490684 [TBL] [Abstract][Full Text] [Related]
6. Hepcidin and Hfe in iron overload in beta-thalassemia. Gardenghi S; Ramos P; Follenzi A; Rao N; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S Ann N Y Acad Sci; 2010 Aug; 1202():221-5. PubMed ID: 20712796 [TBL] [Abstract][Full Text] [Related]
7. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. Gardenghi S; Ramos P; Marongiu MF; Melchiori L; Breda L; Guy E; Muirhead K; Rao N; Roy CN; Andrews NC; Nemeth E; Follenzi A; An X; Mohandas N; Ginzburg Y; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112 [TBL] [Abstract][Full Text] [Related]
8. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia. Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596 [TBL] [Abstract][Full Text] [Related]
9. Hepcidin independent iron recycling in a mouse model of β-thalassaemia intermedia. Frazer DM; Wilkins SJ; Mirciov CS; Dunn LA; Anderson GJ Br J Haematol; 2016 Oct; 175(2):308-317. PubMed ID: 27410488 [TBL] [Abstract][Full Text] [Related]
10. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Kautz L; Jung G; Du X; Gabayan V; Chapman J; Nasoff M; Nemeth E; Ganz T Blood; 2015 Oct; 126(17):2031-7. PubMed ID: 26276665 [TBL] [Abstract][Full Text] [Related]
11. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680 [TBL] [Abstract][Full Text] [Related]
16. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia. Nyffenegger N; Flace A; Doucerain C; Dürrenberger F; Manolova V Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467196 [TBL] [Abstract][Full Text] [Related]
17. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Ginzburg Y; Rivella S Blood; 2011 Oct; 118(16):4321-30. PubMed ID: 21768301 [TBL] [Abstract][Full Text] [Related]
18. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development. Porter J; Taher A; Viprakasit V; Kattamis A; Coates TD; Garbowski M; Dürrenberger F; Manolova V; Richard F; Cappellini MD Expert Rev Hematol; 2021 Jul; 14(7):633-644. PubMed ID: 34324404 [TBL] [Abstract][Full Text] [Related]
19. Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. De Franceschi L; Daraio F; Filippini A; Carturan S; Muchitsch EM; Roetto A; Camaschella C Haematologica; 2006 Oct; 91(10):1336-42. PubMed ID: 17018382 [TBL] [Abstract][Full Text] [Related]
20. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. Guo S; Casu C; Gardenghi S; Booten S; Aghajan M; Peralta R; Watt A; Freier S; Monia BP; Rivella S J Clin Invest; 2013 Apr; 123(4):1531-41. PubMed ID: 23524968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]